Glioblastoma and other gliomas — a hard, immunosuppressed CNS setting where neoantigen vaccines are being tested as early intervention.
One of the primary factors in the development of cancer is the accumulation of genetic mutations. Some of these genetic mutations result in the emergence of unique antigens called neoantigens. These neoantigens are perceived as non-self by T cells, making them prime targets for c…
A review of glioblastoma immunobiology highlights a critical disconnect between murine models and human tumors: patient GBM is enriched for clonally expanded granzyme K+ T cells, whereas standard mouse models show exhausted T cells. This distinction suggests that current preclinical models may misrepresent the targetable neoantigen landscape. The authors argue that harnessing tumor-selective T cells via neoantigen vaccines or adoptive transfer requires a refined focus on these specific human TIL profiles.
Researchers Zhang, Chi, Liu, and colleagues published phase Ib results in Nature Communications for a personalized neoantigen-pulsed autologous dendritic cell therapy in newly diagnosed glioblastoma. The approach isolates patient dendritic cells, pulses them with tumor-specific neoantigens, and reintroduces them to activate cytotoxic T-cells against the heterogeneous tumor. This represents a direct clinical validation of personalized DC vaccine strategies for an aggressive brain cancer with limited treatment options.
GT Biopharma’s GNOS-PV01, a personalized DNA vaccine targeting patient-specific mutations in MGMT-unmethylated glioblastoma, is being evaluated in a Phase 1 study published in Nature Cancer. The trial utilizes multi-regional tumor sampling to address high heterogeneity, aiming to induce immune responses against dozens of neoantigens rather than single targets. This approach addresses the lack of efficacy seen with prior immunotherapies in this aggressive cancer subtype.
Beijing YSCell Biotech is launching an investigator-initiated, open-label Phase 1 trial for YS247, a tumor neoantigen-pulsed autologous dendritic cell injection for recurrent or progressive glioblastoma. The study employs a '3+3' dose-escalation design across three cohorts to assess safety, tolerability, and preliminary efficacy. Patients will receive subcutaneous injections every two weeks for eight doses.
Nature reports that a neoantigen vaccine generated intratumoral T cell responses in a Phase Ib glioblastoma trial. This result is significant for GBM, a tumor type historically resistant to immunotherapy, suggesting that personalized vaccines can successfully prime local immune environments.
Shenzhen Geno-Immune Medical Institute is enrolling by invitation for a Phase 1 trial of an immunomodulatory dendritic cell (DC) vaccine in brain cancer, including glioblastoma and DIPG. The vaccine uses autologous DCs pulsed with genetically modified tumor cells or neoantigens to induce T cell responses linked to improved survival.
The German Cancer Research Center is running a Phase I trial for H3-mutated gliomas. The study targets patients with H3K27M or H3.3K27M mutations using a peptide vaccine designed to exploit neoepitope-specific T cells.
Washington University School of Medicine is assessing a personalized DNA neoantigen vaccine combined with retifanlimab (PD-1 blockade) in newly diagnosed, unmethylated glioblastoma. The Phase I study focuses on safety and immunogenicity.
Beijing Tiantan Hospital has completed a Phase I study evaluating the safety and preliminary efficacy of autologous dendritic cells loaded with tumor neoantigen peptides, administered alongside temozolomide for newly-diagnosed glioblastoma.
The Jonsson Comprehensive Cancer Center is conducting a Phase I trial for H3 G34-mutant diffuse hemispheric glioma. The study tests the safety and optimal dose of a neoantigen-targeted peptide-pulsed dendritic cell (ppDC) vaccine derived from patients' own white blood cells.
ZSky Biotech Inc is preparing a multicenter, open-label, randomized Phase II study for newly diagnosed glioblastoma. The trial compares the efficacy and safety of ZSNeo-DC1.1, a personalized dendritic cell vaccine, combined with temozolomide against temozolomide alone, with progression-free survival as the primary endpoint.
Biogenea Pharmaceuticals is recruiting for an early-phase trial of TamavaqTM, an AI-QMMM designed personalized vaccine for newly diagnosed glioma. The study addresses the unmet need in glioblastoma, where no FDA-approved immunotherapies currently exist, by evaluating safety and therapeutic efficacy of DNA, mRNA, or protein-derived neoantigens.
Washington University School of Medicine is conducting an active, non-recruiting Phase 1 study of a personalized DNA neoantigen vaccine in patients with newly diagnosed, unmethylated glioblastoma. The open-label trial focuses on assessing the safety, feasibility, and immunogenicity of the approach in this aggressive brain cancer subtype.
Dana-Farber Cancer Institute is maintaining an active, not-recruiting phase 1 trial of a personalized neoantigen cancer vaccine combined with radiation and pembrolizumab for newly diagnosed glioblastoma. The study aims to determine safety and define the appropriate dose for future investigations.
Researchers propose a framework to address HLA-Ia downregulation in glioblastoma by integrating HLA-E as an alternative antigen-presentation platform and gamma-delta T cells as effector populations. The strategy combines these biological shifts with AI-assisted neoantigen prioritization and BBB-penetrating delivery technologies to establish a genotype-agnostic foundation for off-the-shelf immunotherapies.
Washington University School of Medicine is running a Phase I study of a personalized neoantigen-based DNA vaccine combined with retifanlimab (PD-1 blockade) in newly diagnosed, unmethylated glioblastoma. The trial assesses safety and immunogenicity, targeting a population with limited therapeutic options.
Beijing Tiantan Hospital completed a Phase I study evaluating autologous dendritic cells loaded with tumor neoantigen peptides alongside temozolomide in newly diagnosed glioblastoma. The trial focused on safety and preliminary efficacy, contributing data on DC-based vaccine platforms in this indication.
CancerNetwork reports that a personalized cancer vaccine combined with pembrolizumab is feasible and effective in patients with newly diagnosed glioblastoma (GBM). This supports the strategy of pairing neoantigen vaccines with PD-1 blockade in aggressive CNS tumors.
Washington University School of Medicine is assessing a personalized neoantigen-based DNA vaccine in newly diagnosed, unmethylated glioblastoma. This trial targets a difficult-to-treat brain cancer subtype, testing the feasibility and immunogenicity of DNA-based delivery in the CNS.
Dana-Farber Cancer Institute is running a Phase 1 trial of a personalized neoantigen cancer vaccine combined with radiation therapy and pembrolizumab for newly diagnosed glioblastoma. The study aims to determine the safety and appropriate dosing of the vaccine, leveraging patient-specific tumor mutations to generate a targeted immunotherapeutic intervention.
Jonsson Comprehensive Cancer Center is running a Phase I trial for a neoantigen-targeted peptide-pulsed dendritic cell (ppDC) vaccine in patients with H3 G34-mutant diffuse hemispheric glioma. The active, non-recruiting study focuses on identifying the best dose and safety profile of this patient-specific immunotherapy.
ZSky Biotech Inc is conducting a multicenter, randomized Phase II study of ZSNeo-DC1.1, a personalized dendritic cell vaccine, combined with temozolomide for newly diagnosed glioblastoma. The trial’s primary endpoint is progression-free survival (PFS) per RANO 2.0 criteria, with exploratory objectives assessing antigen-specific T-cell responses.
Docwire News reports that a personalized neoantigen vaccine has generated immune activity and encouraging survival signals in glioblastoma (GBM). This signal reinforces the clinical viability of personalized approaches in aggressive CNS tumors, though specific sponsor or trial phase details are not provided in the summary.
A Phase 1 trial published in Nature investigates adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma. The study explores the feasibility and immunogenicity of DNA-based platforms in the context of standard adjuvant therapy for this aggressive brain cancer.